Open-label, Multicenter, Phase 1/2 Study of Mogamulizumab in Combination With Nivolumab in Subjects With Locally Advanced or Metastatic Solid Tumors
Active, no longer recruiting
Phase of Trial: Phase I/II
Latest Information Update: 04 Apr 2018
At a glance
- Drugs Mogamulizumab (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Kyowa Hakko Kirin
- 27 Mar 2018 Status changed from recruiting to active, no longer recruiting.
- 14 Feb 2018 Planned End Date changed from 1 Jul 2018 to 1 Oct 2018.
- 14 Feb 2018 Planned primary completion date changed from 1 Jul 2018 to 1 Oct 2018.